The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2016

Filed:

Jun. 03, 2015
Applicants:

Acumen Pharmaceuticals, Inc., Livermore, CA (US);

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

William F. Goure, Livermore, CA (US);

Renee C. Gaspar, West Point, PA (US);

Alexander McCampbell, West Point, PA (US);

Mary J. Savage, West Point, PA (US);

Paul J. Shughrue, West Point, PA (US);

Fubao Wang, West Point, PA (US);

Weirong Wang, West Point, PA (US);

Abigail L. Wolfe, West Point, PA (US);

Ningyan Zhang, West Point, PA (US);

Wei-Qin Zhao, West Point, PA (US);

Min Xu, Ambler, PA (US);

Assignees:

Acumen Pharmaceuticals, Inc., Livermore, CA (US);

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); G01N 33/577 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6896 (2013.01); C07K 16/18 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/4709 (2013.01); G01N 2800/2821 (2013.01);
Abstract

This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.


Find Patent Forward Citations

Loading…